16 maj: Onsdagens aktier: GN taget lidt til nåde i mildere C25
17 maj: NKT/Goldman: Sænker kursmål 20 kr
16-05-2018 23:00:07

Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

Relateret indhold
05 jul - 
NKT er mest shortede aktie i Danmark - men presset afta..
29 jun - 
Fredagens aktier: Nyt slag til Mærsk i ellers positivt ..
29 jun - 
Fredagens aktier: Nyt slag til Mærsk i ellers positivt ..
Relateret debat
13 jul - 
Dette er RSV og ikke kræft
13 jul - 
Historisk er bavarian forsinket med op til 1 år hvad fo..
13 jul - 
Deres talknuser er på Malårka! Kommer hjem i morgen!! M..

COPENHAGEN, Denmark, May 16, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the acceptance of 4 poster presentations and one podium presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 1-5, 2018 in Chicago Illinois. These abstracts are now publicly available online at https://meetinglibrary.asco.org/.

"We are very proud to participate in ASCO, the pre-eminent oncology meeting of the year. We look forward to sharing our progress with the medical community. This includes our phase 3 study of PROSTVAC, which while disappointing in its result, will still provide a number of academic and clinical learnings to the treatment field of prostate cancer, including the advancements in overall survival seen by current standards of care" said Paul Chaplin, President and CEO of Bavarian Nordic. 

"Importantly, the additional posters accepted at ASCO may provide insights into our future development strategies. One study demonstrates the ability of PROSTVAC to drive increased numbers of T cells into newly diagnosed prostate cancer. Another study demonstrated that PROSTVAC combined with nivolumab is safe and has adequate clinical data in advanced metastatic castration resistant prostate cancer to proceed to the planned evaluation of this combination in the neoadjuvant setting of newly diagnosed disease, in cooperation with National Cancer Institute and Bristol-Myers Squibb," Dr. Chaplin concluded.

Presentation and Poster Titles are as follows:

  • Effect of rilimogene galvacirepvec/rilimogene glafolivec (PROSTVAC) on intra/peritumoral immune infiltrate in patients with localized prostate cancer undergoing radical prostatectomy. (Abstract number 5083)

    Poster Session: Genitourinary (Prostate) Cancer. June 2, 2018 from 1:15PM - 4:45PM CDT

  • Combination of a therapeutic cancer vaccine (PROSTVAC) and immune checkpoint inhibitors in prostate cancer. (Abstract number 5084)

    Poster Session: Genitourinary (Prostate) Cancer. June 2, 2018 from 1:15 PM - 4:45 PM CDT

  • A trial of CV301 in combination with anti-PD-1 therapy versus anti-PD-1 therapy in subjects with non-small cell lung cancer. (Abstract number TPS9108)

    Poster Session: Lung Cancer-Non-Small Cell Metastatic. June 3, 2018 from 8:00AM -11:30AM CDT

  • A sequential cohort study of combination immunotherapy with BN-brachyury vaccine, M7824, ALT-803 and epacadostat in metastatic castration-resistant prostate cancer (mCRPC) (QuEST1). (Abstract number TPS3130)

    Poster Session: Developmental Therapeutics - Immunotherapy. June 4, 2018 from 8:00AM-11:30AM CDT

  • Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. (Abstract number 5006)

    Oral Abstract Session: Genitourinary (Prostate) Cancer. June 4, 2018 from 3:00 PM-6:00 PM CDT

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development of innovative and safe therapies against cancer and infectious diseases. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates intended to improve the health and quality of life for children and adults. We supply our IMVAMUNE® non-replicating smallpox vaccine to the U.S. Strategic National Stockpile and other government stockpiles. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Registration studies are currently underway in the U.S. In addition to our long-standing collaboration with the U.S. government on the development of IMVAMUNE® and other medical countermeasures, our infectious disease pipeline comprises a proprietary RSV program as well as vaccine candidates for Ebola, HPV, HBV and HIV, which are developed through a strategic partnership with Janssen. Additionally, in collaboration with the National Cancer Institute, we have developed a portfolio of active cancer immunotherapies, designed to alter the disease course by eliciting a robust and broad anti-cancer immune response while maintaining a favorable risk-benefit profile. Through multiple industry collaborations, we seek to explore the potential synergies of combining our immunotherapies with other immune-modulating agents, e.g. checkpoint inhibitors.

For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Press Release

2018-05-16-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 2018-05-16-en.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
11 jul
BAVA
En uge til 14 dage - vi har den 11/7 i dag, dvs der er gået godt fire uger... Gad vide hvad der ske..
8
10 jul
BAVA
Porten, tak for dine dybe og nuancerede tråde... rart med skribenter der bringer noget til debatten ..
8
13 jul
BAVA
Prostvac - selv om den ikke lykkes i mono terapi køre der uændret en masse fase to forsøg for at und..
4
11 jul
BAVA
ENKOMMENTAR - 1000 Tak for seriøst bidrag, herligt med en sådan deling.   Jeg har lavet lidt noter u..
4
11 jul
BAVA
@enkommentar; Det er forkert når du skriver, at "forsøg som har været afsluttet viser, at vaccinen h..
4
09 jul
BAVA
Baron du er godt nok en være trold 😂😜😄
4
13 jul
BAVA
Kik lige på vedlagte link https://www.clinicaltrials.gov/ct2/show/record/NCT02873286 Jeg kan ikke ..
3
12 jul
BAVA
Den her gang er det som booster til GlaxoSmithKlines ebola vaccine hvor det før var Janssens   https..
2
11 jul
BAVA
Bavarian Nordic offentliggør påbegyndelsen af fase 2 kombinationsforsøg med CV301 og nivolumab i met..
2
09 jul
BAVA
bjoernesaks - Godt spørgsmål de kan begge vinde ... hvem som stiger mest eller mindst er svær at for..
2

Topdanmark/ABG: hæver kursmålet til 270 kr. fra 235 kr.

13-07-2018 14:23:25
Topdanmark får hævet sit kursmål til 270 kr. fra 235 kr. hos ABG Sundal Collier. Det fremgår af Bloomberg News.Opjusteringen af kursmålet ændrer ikke ved anbefalingen, som forbliver "sælg".Forsikringsaktien handles fredag 1 pct. højere i 310,20 kr. frem/ritzau/FINANS

Unibrew/CEO: Nøglefokus er nu på de opkøb vi har foretaget

13-07-2018 08:26:36
Om der er flere opkøb i vente fra Royal Unibrew vil topchefen Hans Savonije ikke oplyse, men han vil have fokus på de opkøb, der nu er foretaget senest med opkøbet af franske Etablissements Geyer Fréres for 660 mio. kr. Det siger han til Ritzau Finans. - Om der er flere opkøb i vente vil jeg ikke oplyse, siger han, og tilføjer:- Vi har en masse på vores tallerken nu. Så nu er fokus på, at de akti..

NKT taber ankesag om kartelbøde

12-07-2018 12:27:34
NKT og ti andre kabelproducenter har tabt en ankesag om en samlet kartelbøde på 302 mio. euro (2,25 mia. kr.), de blev idømt i 2014. Det skriver Bloomberg News.EU-Kommissionen kom dengang frem til, at de 11 kabelselskaber havde ageret som et kartel fra 1999 og godt ti år frem. NKT's andel af bøden var dog kun 3,9 mio. euro, svarende til cirka 29 mio. kr., mens Nexans og Prysmian fik de klart størs..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Bavarian Nordic A/S 192,50 -0,8% Fald i aktiekurs
Bavarian Nordic Ord Shs 192,50 -0,8% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
15. juli 2018 21:28:36
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180712.1 - EUROWEB4 - 2018-07-15 21:28:36 - 2018-07-15 21:28:36 - 1 - Website: OKAY